HomeAbout UsPortfolioNewsContact Us

  • POWER THE COURSE OF FIGHTING DISEASES AND SAVING LIVES

    Domain expertise, global resource, long-term capital

  • PORTFOLIO NEWS

    Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
    2022年12月22日
      RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States...
    Abbisko Therapeutics announces preliminary Phase I safety and efficacy results of Irpagratinib (ABSK011) in patients in second-line hepatocellular carcinoma with FGF19 overexpression
    2022年12月15日
    15 December 2022, Shanghai – Abbisko Therapeutics Co., Ltd. (“Abbisko Therapeutics” hereafter)...
    Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
    2022年11月8日
    -- Agreement includes aggregate upfront and target nomination fees of up to $21.5 million for up...
    Neukio Biotherapeutics completed Series A-1 financing, to accelerate discovery and development of next generation cell therapy products
    2022年9月2日
    SHANGHAI, Sept. 2, 2022 /PRNewswire/ -- Neukio Biotherapeutics, a company committed to developing...
    GluBio Completes Series A+ Financing of $22 Million to Advance the Development of Novel TPD Drugs
    2022年8月1日
    Supported by long-term investors to build leading TPD drug discovery platform and screening...
    Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform
    2022年7月26日
    Rona to advance worldwide development of Sanofi siRNA portfolio targeting liver and other...
    ProfoundBio Announces Completion of $70 Million Series A+ Financing to Advance Antibody-Drug Conjugate (ADC) Programs into the Clinic
    2022年6月2日
    - Advance PRO1184 and PRO1160 into clinical trials - Accelerate multiple programs into...
    Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics
    2022年4月7日
      - Funding from long-term investors to build leading delivery platform and scalable drug...
    More Posts

Company

 

Shanghai

Room 2909-14, 168 Hubin Road, Huangpu District, Shanghai, China.

 

 

Hong Kong

Room 606-7, St. George's Building, 2 Ice House Street, Central, Hong Kong

 

 

US

2735 Sand Hill Road, Suite 210

Menlo Park, CA 94025

copyright © 2018 Lilly Asia Ventures all rights reserved.

沪公网安备 31010102005458号
|
沪ICP备12003647号-1
    All Posts
    ×
    Cookie Use
    We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
    Learn More